IL6 and gastric cancer: Another study by Liao et al. [65] showed that in patients with stage II or III GC (n = 86), survival time was significantly longer (1418 days) for patients with serum IL-6 levels ≤13 pg/mL, as opposed to 618 days in patients with serum IL-6 levels >13 pg/mL.